 Anne McCall
| Title | Associate Professor |
|---|
| Institution | University of Chicago |
|---|
| Department | Radiation & Cellular Oncology |
|---|
| Address | Chicago IL 60637
|
|---|
| vCard | Download vCard |
|---|
|
|
|
 Overview Anne R. McCall, MD, is an expert in radiation oncology, specializing in the treatment of breast cancer, gynecologic cancers, lymphoma, lung cancer, prostate cancer and solid tumors. She uses the leading-edge TrueBeam™ system to deliver a range of radiation therapies. This innovative technology is highly accurate -- allowing for faster, more comfortable treatment while minimizing damage to healthy tissue.
In addition to her clinical work, Dr. McCall is interested in translational research -- the process by which discoveries made in the lab are brought to patient populations. She also has a strong interest in cost-benefit analyses, including the economic impact of shorter radiation regimens for patients diagnosed with early stage breast cancer.
Dr. McCall is regularly named one of the "Best Doctors in America" by Best Doctors, Inc. and is an active member of the Leadership Board of the Prairie Land Region of the American Cancer Society.
Biography | Rush University Medical College | MD | | | | Loyola University Medical Center | Internship | | | | Loyola University Medical Center | Residency | | | | Loyola University Medical Center | Fellowship | | |
Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
Faculty can login to make corrections and additions.
-
Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A, Golden D, Jolly S, Fleming G, Morrow M, Kraynyak K, Sylvester A, Arif F, Levin M, Schwartz D, Boyer J, Skolnik J, Esser M, Kumar R, Bagarazzi M, Weichselbaum R, Spiotto M. A Phase I trial assessing the safety and tolerability of a therapeutic DNA vaccination against HPV16 and HPV18 E6/E7 oncogenes after chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys. 2020 Mar 06. PMID: 32151670.
-
Foster CC, Hasan Y, Son CH, McCall AR. In Reply to Trombetta. Int J Radiat Oncol Biol Phys. 2019 11 15; 105(4):904-905. PMID: 31655659.
-
Arya R, Ichikawa T, Callender B, Schultz O, DePablo M, Novak K, Li S, Shenoy A, Everman A, Braunstein S, Dec I, Lala S, Feng Y, Biltz L, McCall AR, Golden DW. Communicating the External Beam Radiation Experience (CEBRE): Perceived Benefits of a Graphic Narrative Patient Education Tool. Pract Radiat Oncol. 2019 Sep 11. PMID: 31520767.
-
Foster CC, Hasan Y, Son CH, McCall AR. Linearly Accelerating Toward Gender Equity in Radiation Oncology. Int J Radiat Oncol Biol Phys. 2019 08 01; 104(5):974-978. PMID: 31327430.
-
Ni L, Koshy M, Connell P, Pitroda S, Golden DW, Al-Hallaq H, Hubert G, Kauffman G, McCall A, Malik R. Heart V5 predicts cardiac events in unresectable lung cancer patients undergoing chemoradiation. J Thorac Dis. 2019 Jun; 11(6):2229-2239. PMID: 31372260.
-
Perni S, Rooney MK, Horowitz DP, Golden DW, McCall AR, Einstein AJ, Jagsi R. Assessment of Use, Specificity, and Readability of Written Clinical Informed Consent Forms for Patients With Cancer Undergoing Radiotherapy. JAMA Oncol. 2019 May 02; e190260. PMID: 31046122.
-
Das LC, Golden DW, Perevalova E, Wong AC, De Nardo K, Stepaniak C, Joyce DS, McCabe BP, Hasan Y, Chmura SJ, McCall A. A feasibility study of 2-mm bolus for postmastectomy radiation therapy. Pract Radiat Oncol. 2017 May - Jun; 7(3):161-166. PMID: 28089526.
-
Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant. 2003 Aug; 9(8):529-39. PMID: 12931122.
-
Nieland JD, Loviscek K, Kono K, Albain KS, McCall AR, Potkul RK, Fisher SG, Velders MP, Petersson M, Kiessling R, Kast WM. PBLs of early breast carcinoma patients with a high nuclear grade tumor unlike PBLs of cervical carcinoma patients do not show a decreased TCR zeta expression but are functionally impaired. J Immunother. 1998 Jul; 21(4):317-22. PMID: 9672853.
-
Mohideen MN, McCall AR, Feinstein J, Sidrys J, Bricker P, Luka S. Factors that influence biochemical failure after radiation therapy for stage T1c prostate cancer. Am J Clin Oncol. 1998 Feb; 21(1):6-11. PMID: 9499260.
-
Dolan JR, McCall AR, Gooneratne S, Walter S, Lansky DM. DNA ploidy, proliferation index, grade, and stage as prognostic factors for vulvar squamous cell carcinomas. Gynecol Oncol. 1993 Feb; 48(2):232-5. PMID: 8428696.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
| Year | Publications |
|---|
| 1993 | 1 | | 1998 | 2 | | 2003 | 1 | | 2016 | 1 | | 2019 | 5 | | 2020 | 1 |
To return to the timeline, click here.
|
McCall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|